Study title:
Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study - Bukstein DA, Bratton DI, Firriolo KM, Estojak J, Bird SR et al. 2003 (J Asthma 2003;40:475-85)
Publication in CES clinical expert statement - Bruno Verdoncq - 28/08/07Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study - Bukstein DA, Bratton DI, Firriolo KM, Estojak J, Bird SR et al. 2003 (J Asthma 2003;40:475-85)
Publication in CES clinical expert statement - Bruno Verdoncq - 28/08/07
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Respiratory Tract Diseases
|
Brands: Please see report, Please see report, Please see report |
MAH holders: Please see report, Please see report, Please see report, Please see report |
Assessment: |
Active substance: CROMOGLICIC ACID |
ATC code: |
Document link:
|
Document date:
|
Study number: - |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|